Evidence map›Paper›PMID 41930192›Full record

ArticleFrontiers in oncology2026

Gastric cancer in Abidjan: care strategies and survival in a resource-limited setting.

Kouamé Konan Yvon Kouassi, Yénahaban Lazare Touré, Bitti Addé Odo, Pétiori Gningayou Laurence Touré, N'Guessan Manlan Prosper Mébiala, Fleur Audrey Sességnon, Akissi Marie Barbara Yvonne Nogbou, Mohamed Kassir Agnidé Madiou, Ibrahima Alhassane Cissé, Moctar Touré and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kouamé Konan Yvon KouassiMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.
Yénahaban Lazare TouréMedical Oncology Department, Bouaké University Hospital Center, Bouaké, Côte d'Ivoire.
Bitti Addé OdoMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.
Pétiori Gningayou Laurence TouréMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.
N'Guessan Manlan Prosper MébialaMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.
Fleur Audrey SességnonMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.
Akissi Marie Barbara Yvonne NogbouMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.
Mohamed Kassir Agnidé MadiouMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.
Ibrahima Alhassane CisséMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.
Moctar TouréMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.
Innocent AdoubiMedical Oncology Department, Treichville University Hospital Center, Abidjan, Côte d'Ivoire.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In Côte d'Ivoire, the management of gastric cancer relies mainly on chemotherapy and surgery. However, the actual impact of these treatments on patient survival remains poorly documented. Objective: To evaluate management strategies and clinical outcomes of patients with gastric cancer in Abidjan. Methods: A 5-year retrospective cohort study was conducted across five hospitals in Abidjan. All patients followed for gastric cancer were included. Clinical, therapeutic, and outcome data were analyzed using SPSS, with a significance threshold set at p < 0.05. Results: Seventy-seven patients were included (mean age: 56.9 years; male-to-female ratio: 2.8). Consultation was often delayed (>3 months after symptom onset). Metastatic disease accounted for 60.7% of cases. Adenocarcinoma was the predominant histological type (98.7%). A multidisciplinary tumor board (MTB) was held in only 37.7% of cases. Initial treatment was surgical (49.4%), palliative/supportive (26%), or chemotherapy-based (23.4%). Median survival was 15 months. Disease stage at diagnosis and consultation delay significantly influenced survival. Conclusion: Gastric cancer is managed in Abidjan, but major gaps remain, particularly the lack of systematic MTB discussion and late diagnosis. Broader access to innovative therapies and the implementation of early detection strategies are urgently needed to improve outcomes.

Indexed as

AbidjanCôte d’Ivoiregastric cancermanagementsurvival

Identifiers

PMID41930192
PMCPMC13038569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.